INDICATIONS
Indications
  • KYPROLIS® (carfilzomib) is indicated in combination with dexamethasone, or with lenalidomide plus dexamethasone, or with daratumumab plus dexamethasone, or with daratumumab plus hyaluronidase-fihj plus dexamethasone, or with isatuximab plus dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy.Read More
  • KYPROLIS® is indicated as a single agent for the treatment of patients with relapsed or refractory multiple myeloma who have received one or more lines of therapy.Close
    • ... Read More  Read Less
HCP Site | Patient Site
Important Safety Information Indications Prescribing Information Connect with a rep
KYPROLIS® (carfilzomibz) for injection logo
mob_search_icon
hamburger _icon_open

Isa-Kd:

KYPROLIS® + isatuximab-irfc + dexamethasone

Proven to bring a deep and durable response

Isa-Kd vs Kd study design (IKEMA): Randomized, open-label, multicenter trial of 302 patients with RRMM who were randomized 3:2 to receive Isa-Kd (n = 179) or Kd (n = 123) with KYPROLIS® 56 mg/m² twice weekly. As of the primary analysis, with a median follow-up of 20.7 months, the study met its primary endpoint of improved PFS. Median PFS was not reached with Isa-Kd vs 20.27 months with Kd (HR = 0.55; 95% CI: 0.37-0.82; P = 0.0032).1,2

Power what’s possible with a median of nearly
42 months of progression-free survival3,*

Isa-Kd vs Kd: Progression free survival graph
41.7 months progression-free survival

At a median follow-up of 44 months, mPFS was 41.7 months with Isa-Kd vs 20.8 months with Kd3

HR = 0.59; 95.4% CI: 0.42-0.83

*Analysis censoring PFS events occurring > 8 weeks from the last valid disease assessment.

Pairing Isa with Kd delivered deep responses for patients1,5

As ORR did not reach statistical significance, ≥ VGPR, MRD-, and CR were analyzed for descriptive purposes only. According to the FDA, MRD should be assessed only in patients who are in CR. In IKEMA, MRD was assessed in patients who achieved ≥ VGPR, therefore this analysis requires cautious interpretation.3

CI = confidence interval; CR = complete response; HR = hazard ratio;
Isa-Kd = carfilzomib + isatuximab-irfc + dexamethasone; Kd = carfilzomib + dexamethasone; mg/kg = milligrams per kilogram; mPFS = median progression-free survival; MRD = minimal residual disease; ORR = overall response rate;
PFS = progression-free survival; VGPR = very good partial response.

Subgroup analysis in specific patient populations*

Consistent PFS benefit seen with Isa-Kd across subgroups

1 prior line of therapy

0.71

PFS hazard ratio3

95% CI (0.445-1.138);

Events, n/N (Isa-Kd = 41/80; Kd = 31/55)

Lenalidomide refractory

0.59

PFS hazard ratio3

95% CI (0.353-0.972);

Events, n/N (Isa-Kd = 31/57; Kd = 30/42)

High-risk cytogenetics†

0.72

PFS hazard ratio3

95% CI (0.406-1.290);

Events, n/N (Isa-Kd = 26/42; Kd = 21/31)

Subgroups were preplanned, except for lenalidomide refractoriness. Analyses were not adjusted for multiplicity or powered to detect differences within subgroups and results should be considered descriptive and exploratory.2

*Analysis in the ITT population per IRC censoring for further anti-myeloma treatment.

†High-risk cytogenetic status is defined as the presence of del(17p) or translocation t(4;14) or translocation t(14;16); chromosomal abnormality was considered positive if present in at least 30% of analysed plasma cells, except for del(17p) where the threshold is at least 50%.

IRC = independent response committee; Isa-Kd = carfilzomib + isatuximab-irfc + dexamethasone; ITT = intent to treat; Kd = carfilzomib + dexamethasone; PFS = progression-free survival.

Study Design

Isa-Kd vs Kd (IKEMA)

Isa-Kd vs Kd in RRMM IKEMA study design

Randomized, open-label, multicenter trial of 302 patients with RRMM who were randomized 3:2 to receive Isa-Kd (n = 179) or Kd (n = 123) with KYPROLIS® 56 mg/m² twice weekly. As of the primary analysis, with a median follow-up of 20.7 months, the study met its primary endpoint of improved PFS. Median PFS was not reached with Isa-Kd vs 20.27 months with Kd (HR = 0.55; 95% CI: 0.37-0.82; P = 0.0032).2,3

Inclusion and exclusion criteria1,2

Key eligibility criteria (N = 302):

  • ≥ 18 years
  • 1 to 3 prior lines of therapy
  • M-protein ≥ 0.5 g/dL and/or urine M-protein ≥ 200 mg/24h
  • ECOG PS 0-2

Key exclusion criteria:

  • Primary refractory multiple myeloma
  • Serum-free light chain measurable disease (only)
  • Prior carfilzomib treatment
  • Refractory to§ or failed to achieve at least minimal response with prior anti-CD38 therapy
  • Prior allogeneic stem cell transplant with active graft vs host disease

*Carfilzomib at 56 mg/m2 is administered twice weekly; 20 mg/m2 on Days 1 and 2 of Cycle 1 only.

†Isatuximab 10 mg/kg was administered as an IV infusion weekly in the first cycle and every two weeks thereafter.

‡Dexamethasone 20 mg was given on days 1, 2, 8, 9, 15, 16, 22, and 23 for each 28-day cycle. On the days where both isatuximab-irfc and carfilzomib were administered, dexamethasone was administered first, followed by isatuximab-irfc infusion, then followed by carfilzomib infusion.

§Progression on or within 60 days after the end of anti-CD38 therapy.

BIW = twice a week; CD38 = cluster of differentiation 38; CR = complete response; ECOG PS = Eastern Cooperative Oncology Group performance status;
Isa-Kd = carfilzomib + isatuximab-irfc + dexamethasone; Kd = carfilzomib + dexamethasone; R = randomization; M-protein = monoclonal protein; MRD = minimal residual disease; ORR = overall response rate; OS = overall survival;
PFS = progression-free survival; VGPR = very good partial response.

Patient demographics and baseline characteristics2
Characteristics Isa-Kd (n=179) Kd (n=123)
Median age (IQR) 65 (55-70) 63 (57-70)
Age, n (%) < 65 years 88 (49) 66 (54)
65-74 years 74 (41) 47 (38)
≥ 75 years 17 (9) 10 (8)
Gender, n (%) Female 78 (44) 55 (45)
Male 101 (56) 68 (55)
Race, n (%) Asian 26 (15) 24 (20)
Black or African American 5 (3) 4 (3)
White 131 (73) 83 (67)
Other or not reported 17 (9) 12 (10)
eGFR, (MDRD),* n (%) < 60 mL/min per 1.73 m2 43 (26) 18 (16)
≥ 60 mL/min per 1.73 m2 122 (74) 93 (84)
0 95 (53) 73 (59)
ECOG PS, n (%) 1 73 (41) 45 (37)
2 10 (6) 5 (4)
3 1 (1) 0
I 89 (50) 71 (58)
ISS stage at study entry, n (%) II 63 (35) 31 (25)
III 26 (15) 20 (16)
Unknown 1 (1) 1 (1)
High-risk chromosomal abnormality† 42 (23) 31 (25)
Cytogenetic risk at baseline, n (%) Standard-risk chromosomal abnormality 114 (64) 78 (63)
Unknown or missing 23 (13) 14 (11)
Number or previous lines of therapy Median therapies, (range) 2 (1-2) 2 (1-3)
Proteasome inhibitors 166 (93) 105 (85)
Prior therapies, n (%) Lenalidomide 72 (40) 59 (48)
Refractory to lenalidomide 57 (32) 42 (34)
Characteristics Isa-Kd (n=179) Kd (n=123)
Age, n (%)
Median age (IQR) 65 (55-70) 63 (57-70)
< 65 years 88 (49) 66 (54)
65-74 years 74 (41) 47 (38)
≥ 75 years 17 (9) 10 (8)
Gender, n (%)
Female 78 (44) 55 (45)
Male 101 (56) 68 (55)
Race, n (%)
Asian 26 (15) 24 (20)
Black or African American 5 (3) 4 (3)
White 131 (73) 83 (67)
Other or not reported 17 (9) 12 (10)
eGFR, (MDRD),* n (%)
< 60 mL/min per 1.73 m2 43 (26) 18 (16)
≥ 60 mL/min per 1.73 m2 122 (74) 93 (84)
ECOG PS, n (%)
0 95 (53) 73 (59)
1 73 (41) 45 (37)
2 10 (6) 5 (4)
3 1 (1) 0
ISS stage at study entry, n (%)
I 89 (50) 71 (58)
II 63 (35) 31 (25)
III 26 (15) 20 (16)
Unknown 1 (1) 1 (1)
Cytogenetic risk at baseline, n (%)
High-risk chromosomal abnormality† 42 (23) 31 (25)
Standard-risk chromosomal abnormality 114 (64) 78 (63)
Unknown or missing 23 (13) 14 (11)
Number or previous lines of therapy
Median therapies, (range) 2 (1-2) 2 (1-3)
Prior therapies, n (%)
Proteasome inhibitors 166 (93) 105 (85)
Lenalidomide 72 (40) 59 (48)
Refractory to lenalidomide 57 (32) 42 (34)

Data are median (IQR) or n (%).

*Incidence calculated in patients with race reported in case report form—165 patients in the isatuximab group and 111 patients in the control group.2

†High-risk cytogenetic status is defined as the presence of del(17p) or translocation t(4;14) or translocation t(14;16); chromosomal abnormality was considered positive if present in at least 30% of analyzed plasma cells, except for del(17p) where the threshold is at least 50%.2

eGFR = estimated glomerular filtration rate; MDRD = modification of diet in renal disease; ISS = International Staging System; IQR = interquartile range.

SafetySafety

Safety

Learn more about Isa-Kd safety information
Infusion bag and syringeInfusion bag and syringe

Dosing

With Isa-Kd, KYPROLIS® is dosed 2x weekly6

Isa-Kd = carfilzomib + isatuximab-irfc + dexamethasone.

EXPAND

IMPORTANT SAFETY INFORMATION FOR KYPROLIS®

Cardiac Toxicities

  • New onset or worsening of pre-existing cardiac failure (e.g., congestive heart failure, pulmonary edema, decreased ejection fraction), cardiomyopathy, myocardial ischemia, and myocardial infarction including fatalities have occurred following administration of KYPROLIS®. Some events occurred in patients with normal baseline ventricular function. Death due to cardiac arrest has occurred within one day of administration.
  • Monitor patients for signs or symptoms of cardiac failure or ischemia. Evaluate promptly if cardiac toxicity is suspected. Withhold KYPROLIS® for Grade 3 or 4 cardiac adverse reactions until recovery, and consider whether to restart at 1 dose level reduction based on a benefit/risk assessment.
  • While adequate hydration is required prior to each dose in Cycle 1, monitor all patients for evidence of volume overload, especially patients at risk for cardiac failure. Adjust total fluid intake as clinically appropriate.
  • For patients ≥ 75 years, the risk of cardiac failure is increased. Patients with New York Heart Association Class III and IV heart failure, recent myocardial infarction, conduction abnormalities, angina, or arrhythmias may be at greater risk for cardiac complications and should have a comprehensive medical assessment prior to starting treatment with KYPROLIS® and remain under close follow-up with fluid management.

Acute Renal Failure

  • Cases of acute renal failure, including some fatal renal failure events, and renal insufficiency (including renal failure) have occurred. Acute renal failure was reported more frequently in patients with advanced relapsed and refractory multiple myeloma who received KYPROLIS® monotherapy. Monitor renal function with regular measurement of the serum creatinine and/or estimated creatinine clearance. Reduce or withhold dose as appropriate.

Tumor Lysis Syndrome

  • Cases of Tumor Lysis Syndrome (TLS), including fatal outcomes, have occurred. Patients with a high tumor burden should be considered at greater risk for TLS. Adequate hydration is required prior to each dose in Cycle 1, and in subsequent cycles as needed. Consider uric acid lowering drugs in patients at risk for TLS. Monitor for evidence of TLS during treatment and manage promptly, and withhold until resolved.

Pulmonary Toxicity

  • Acute Respiratory Distress Syndrome (ARDS), acute respiratory failure, and acute diffuse infiltrative pulmonary disease such as pneumonitis and interstitial lung disease have occurred. Some events have been fatal. In the event of drug-induced pulmonary toxicity, discontinue KYPROLIS®.

Pulmonary Hypertension

  • Pulmonary arterial hypertension (PAH) was reported. Evaluate with cardiac imaging and/or other tests as indicated. Withhold KYPROLIS® for PAH until resolved or returned to baseline and consider whether to restart based on a benefit/risk assessment.

Dyspnea

  • Dyspnea was reported in patients treated with KYPROLIS®. Evaluate dyspnea to exclude cardiopulmonary conditions including cardiac failure and pulmonary syndromes. Stop KYPROLIS® for Grade 3 or 4 dyspnea until resolved or returned to baseline. Consider whether to restart based on a benefit/risk assessment.

Hypertension

  • Hypertension, including hypertensive crisis and hypertensive emergency, has been observed, some fatal. Control hypertension prior to starting KYPROLIS®. Monitor blood pressure regularly in all patients. If hypertension cannot be adequately controlled, withhold KYPROLIS® and evaluate. Consider whether to restart based on a benefit/risk assessment.

Venous Thrombosis

  • Venous thromboembolic events (including deep venous thrombosis and pulmonary embolism) have been observed. Provide thromboprophylaxis for patients being treated with the combination of KYPROLIS® with dexamethasone or with lenalidomide plus dexamethasone or with daratumumab and dexamethasone. The thromboprophylaxis regimen should be based on an assessment of the patient’s underlying risks.
  • For patients using hormonal contraception associated with a risk of thrombosis, consider an alternative method of effective contraception during treatment.

Infusion-Related Reactions

  • Infusion-related reactions, including life-threatening reactions, have occurred. Signs and symptoms include fever, chills, arthralgia, myalgia, facial flushing, facial edema, laryngeal edema, vomiting, weakness, shortness of breath, hypotension, syncope, chest tightness, or angina. These reactions can occur immediately following or up to 24 hours after administration. Premedicate with dexamethasone to reduce the incidence and severity of infusion-related reactions.

Hemorrhage

  • Fatal or serious cases of hemorrhage have been reported. Hemorrhagic events have included gastrointestinal, pulmonary, and intracranial hemorrhage and epistaxis. Promptly evaluate signs and symptoms of blood loss. Reduce or withhold dose as appropriate.

Thrombocytopenia

  • KYPROLIS® causes thrombocytopenia with recovery to baseline platelet count usually by the start of the next cycle. Monitor platelet counts frequently during treatment. Reduce or withhold dose as appropriate.

Hepatic Toxicity and Hepatic Failure

  • Cases of hepatic failure, including fatal cases, have occurred. KYPROLIS® can cause increased serum transaminases. Monitor liver enzymes regularly regardless of baseline values. Reduce or withhold dose as appropriate.

Thrombotic Microangiopathy

  • Cases of thrombotic microangiopathy, including thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS), including fatal outcome, have occurred. Monitor for signs and symptoms of TTP/HUS. Discontinue if diagnosis is suspected. If the diagnosis of TTP/HUS is excluded, KYPROLIS® may be restarted. The safety of reinitiating KYPROLIS® is not known.

Posterior Reversible Encephalopathy Syndrome (PRES)

  • Cases of PRES have occurred in patients receiving KYPROLIS®. If PRES is suspected, discontinue and evaluate with appropriate imaging. The safety of reinitiating KYPROLIS® is not known.

Progressive Multifocal Leukoencephalopathy (PML)

  • Cases of PML, including fatal cases, have occurred. In addition to KYPROLIS®, other contributary factors may include prior or concurrent use of immunosuppressive therapy. Consider PML in any patient with new onset of or changes in pre-existing neurological signs or symptoms. If PML is suspected, discontinue and initiate evaluation for PML including neurology consultation.

Increased Fatal and Serious Toxicities in Combination with Melphalan and Prednisone in Newly Diagnosed Transplant-ineligible Patients

  • In a clinical trial of transplant-ineligible patients with newly diagnosed multiple myeloma comparing KYPROLIS®, melphalan, and prednisone (KMP) vs bortezomib, melphalan, and prednisone (VMP), a higher incidence of serious and fatal adverse reactions was observed in patients in the KMP arm. KMP is not indicated for transplant-ineligible patients with newly diagnosed multiple myeloma.

Embryo-fetal Toxicity

  • KYPROLIS® can cause fetal harm when administered to a pregnant woman.
  • Advise pregnant women of the potential risk to a fetus. Females of reproductive potential should use effective contraception during treatment with KYPROLIS® and for 6 months following the final dose. Males of reproductive potential should use effective contraception during treatment with KYPROLIS® and for 3 months following the final dose.

Adverse Reactions

  • The most common adverse reactions occurring in at least 20% of patients taking KYPROLIS® in the combination therapy trials: anemia, diarrhea, hypertension, fatigue, upper respiratory tract infection, thrombocytopenia, pyrexia, cough, dyspnea, and insomnia.
  • The most common adverse reactions occurring in at least 20% of patients taking KYPROLIS® in monotherapy trials: anemia, fatigue, thrombocytopenia, nausea, pyrexia, dyspnea, diarrhea, headache, cough, edema peripheral.

Please see accompanying full Prescribing Information.

INDICATIONS

  • KYPROLIS® (carfilzomib) is indicated in combination with dexamethasone, or with lenalidomide plus dexamethasone, or with daratumumab plus dexamethasone, or with daratumumab plus hyaluronidase-fihj plus dexamethasone, or with isatuximab plus dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy.
  • KYPROLIS® is indicated as a single agent for the treatment of patients with relapsed or refractory multiple myeloma who have received one or more lines of therapy.

IMPORTANT SAFETY INFORMATION FOR KYPROLIS®

Cardiac Toxicities

  • New onset or worsening of pre-existing cardiac failure (e.g., congestive heart failure, pulmonary edema, decreased ejection fraction), cardiomyopathy, myocardial ischemia, and myocardial infarction including fatalities have occurred following administration of KYPROLIS®. Some events occurred in patients with normal baseline ventricular function. Death due to cardiac arrest has occurred within one day of administration.
  • Monitor patients for signs or symptoms of cardiac failure or ischemia. Evaluate promptly if cardiac toxicity is suspected. Withhold KYPROLIS® for Grade 3 or 4 cardiac adverse reactions until recovery, and consider whether to restart at 1 dose level reduction based on a benefit/risk assessment.
  • While adequate hydration is required prior to each dose in Cycle 1, monitor all patients for evidence of volume overload, especially patients at risk for cardiac failure. Adjust total fluid intake as clinically appropriate.
  • For patients ≥ 75 years, the risk of cardiac failure is increased. Patients with New York Heart Association Class III and IV heart failure, recent myocardial infarction, conduction abnormalities, angina, or arrhythmias may be at greater risk for cardiac complications and should have a comprehensive medical assessment prior to starting treatment with KYPROLIS® and remain under close follow-up with fluid management.

Acute Renal Failure

  • Cases of acute renal failure, including some fatal renal failure events, and renal insufficiency (including renal failure) have occurred. Acute renal failure was reported more frequently in patients with advanced relapsed and refractory multiple myeloma who received KYPROLIS® monotherapy. Monitor renal function with regular measurement of the serum creatinine and/or estimated creatinine clearance. Reduce or withhold dose as appropriate.

Tumor Lysis Syndrome

  • Cases of Tumor Lysis Syndrome (TLS), including fatal outcomes, have occurred. Patients with a high tumor burden should be considered at greater risk for TLS. Adequate hydration is required prior to each dose in Cycle 1, and in subsequent cycles as needed. Consider uric acid lowering drugs in patients at risk for TLS. Monitor for evidence of TLS during treatment and manage promptly, and withhold until resolved.

Pulmonary Toxicity

  • Acute Respiratory Distress Syndrome (ARDS), acute respiratory failure, and acute diffuse infiltrative pulmonary disease such as pneumonitis and interstitial lung disease have occurred. Some events have been fatal. In the event of drug-induced pulmonary toxicity, discontinue KYPROLIS®.

Pulmonary Hypertension

  • Pulmonary arterial hypertension (PAH) was reported. Evaluate with cardiac imaging and/or other tests as indicated. Withhold KYPROLIS® for PAH until resolved or returned to baseline and consider whether to restart based on a benefit/risk assessment.

Dyspnea

  • Dyspnea was reported in patients treated with KYPROLIS®. Evaluate dyspnea to exclude cardiopulmonary conditions including cardiac failure and pulmonary syndromes. Stop KYPROLIS® for Grade 3 or 4 dyspnea until resolved or returned to baseline. Consider whether to restart based on a benefit/risk assessment.

Hypertension

  • Hypertension, including hypertensive crisis and hypertensive emergency, has been observed, some fatal. Control hypertension prior to starting KYPROLIS®. Monitor blood pressure regularly in all patients. If hypertension cannot be adequately controlled, withhold KYPROLIS® and evaluate. Consider whether to restart based on a benefit/risk assessment.

Venous Thrombosis

  • Venous thromboembolic events (including deep venous thrombosis and pulmonary embolism) have been observed. Provide thromboprophylaxis for patients being treated with the combination of KYPROLIS® with dexamethasone or with lenalidomide plus dexamethasone or with daratumumab and dexamethasone. The thromboprophylaxis regimen should be based on an assessment of the patient’s underlying risks.
  • For patients using hormonal contraception associated with a risk of thrombosis, consider an alternative method of effective contraception during treatment.

Infusion-Related Reactions

  • Infusion-related reactions, including life-threatening reactions, have occurred. Signs and symptoms include fever, chills, arthralgia, myalgia, facial flushing, facial edema, laryngeal edema, vomiting, weakness, shortness of breath, hypotension, syncope, chest tightness, or angina. These reactions can occur immediately following or up to 24 hours after administration. Premedicate with dexamethasone to reduce the incidence and severity of infusion-related reactions.

Hemorrhage

  • Fatal or serious cases of hemorrhage have been reported. Hemorrhagic events have included gastrointestinal, pulmonary, and intracranial hemorrhage and epistaxis. Promptly evaluate signs and symptoms of blood loss. Reduce or withhold dose as appropriate.

Thrombocytopenia

  • KYPROLIS® causes thrombocytopenia with recovery to baseline platelet count usually by the start of the next cycle. Monitor platelet counts frequently during treatment. Reduce or withhold dose as appropriate.

Hepatic Toxicity and Hepatic Failure

  • Cases of hepatic failure, including fatal cases, have occurred. KYPROLIS® can cause increased serum transaminases. Monitor liver enzymes regularly regardless of baseline values. Reduce or withhold dose as appropriate.

Thrombotic Microangiopathy

  • Cases of thrombotic microangiopathy, including thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS), including fatal outcome, have occurred. Monitor for signs and symptoms of TTP/HUS. Discontinue if diagnosis is suspected. If the diagnosis of TTP/HUS is excluded, KYPROLIS® may be restarted. The safety of reinitiating KYPROLIS® is not known.

Posterior Reversible Encephalopathy Syndrome (PRES)

  • Cases of PRES have occurred in patients receiving KYPROLIS®. If PRES is suspected, discontinue and evaluate with appropriate imaging. The safety of reinitiating KYPROLIS® is not known.

Progressive Multifocal Leukoencephalopathy (PML)

  • Cases of PML, including fatal cases, have occurred. In addition to KYPROLIS®, other contributary factors may include prior or concurrent use of immunosuppressive therapy. Consider PML in any patient with new onset of or changes in pre-existing neurological signs or symptoms. If PML is suspected, discontinue and initiate evaluation for PML including neurology consultation.

Increased Fatal and Serious Toxicities in Combination with Melphalan and Prednisone in Newly Diagnosed Transplant-ineligible Patients

  • In a clinical trial of transplant-ineligible patients with newly diagnosed multiple myeloma comparing KYPROLIS®, melphalan, and prednisone (KMP) vs bortezomib, melphalan, and prednisone (VMP), a higher incidence of serious and fatal adverse reactions was observed in patients in the KMP arm. KMP is not indicated for transplant-ineligible patients with newly diagnosed multiple myeloma.

Embryo-fetal Toxicity

  • KYPROLIS® can cause fetal harm when administered to a pregnant woman.
  • Advise pregnant women of the potential risk to a fetus. Females of reproductive potential should use effective contraception during treatment with KYPROLIS® and for 6 months following the final dose. Males of reproductive potential should use effective contraception during treatment with KYPROLIS® and for 3 months following the final dose.

Adverse Reactions

  • The most common adverse reactions occurring in at least 20% of patients taking KYPROLIS® in the combination therapy trials: anemia, diarrhea, hypertension, fatigue, upper respiratory tract infection, thrombocytopenia, pyrexia, cough, dyspnea, and insomnia.
  • The most common adverse reactions occurring in at least 20% of patients taking KYPROLIS® in monotherapy trials: anemia, fatigue, thrombocytopenia, nausea, pyrexia, dyspnea, diarrhea, headache, cough, edema peripheral.

Please see accompanying full Prescribing Information.

INDICATIONS

  • KYPROLIS® (carfilzomib) is indicated in combination with dexamethasone, or with lenalidomide plus dexamethasone, or with daratumumab plus dexamethasone, or with daratumumab plus hyaluronidase-fihj plus dexamethasone, or with isatuximab plus dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy.
  • KYPROLIS® is indicated as a single agent for the treatment of patients with relapsed or refractory multiple myeloma who have received one or more lines of therapy.
Back To Top

References: 1. SARCLISA® (isatuximab-irfc) prescribing information. Bridgewater, NJ: sanofi-aventis U.S. LLC. 2. Moreau P, Dimopoulos MA, Mikhael J, et al. Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial. Lancet. 2021;397:2361-2371. 3. Martin T, Dimopoulos MA, Mikhael J, et al. Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study. Blood Cancer J. 2023;13:72. 4. Martin T, Dimopoulos MA, Mikhael J, et al. Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study. Blood Cancer J. 2023;13(suppl):1-12. 5. Moreau P, Dimopoulos MA, Mikhael J, et al. Updated progression-free survival and depth of response in IKEMA, a randomized phase III trial of isatuximab, carfilzomib and dexamethasone (Isa-Kd) vs Kd in relapsed multiple myeloma. Presented at: ESMO Virtual Plenary, University Hospital Hôtel-Dieu; May 19-20, 2022; Nantes, France. 6. KYPROLIS® (carfilzomib) prescribing information, Onyx Pharmaceuticals Inc., an Amgen Inc. subsidiary.